Not finding it? Sign in to also search OpenAlex live.
-
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
Susanne Isfort, Kirsi Marjaana Manz, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +20 more
17citations -
Ultrafine Fe-Fe2Ti eutectics by directed energy deposition: Insights into microstructure formation based on experimental techniques and phase field modelling2020 Additive manufacturing article Materials Science Solidification and crystal growth phenomena Open access
Guillermo Carlos Requena, Katrin Bugelnig, Federico Sket, Srdjan Milenković, Georg Rödler, Andreas Weisheit, +8 more
16citations -
Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
Susanne Isfort, Kirsi Marjaana Manz, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +18 more
0citations -
Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study
Larysa Jessica Sanchez, Carolina Schinke, Amrita Y. Krishnan, Jesús G. Berdeja, Niels W.C.J. van de Donk, María‐Victoria Mateos, +19 more
18citations -
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib
Jayesh Desai, Andrew J. Wagner, Irene Carrasco García, Marilena Cesari, Chia‐Chi Lin, Zsuzsanna Pápai, +11 more
10citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Ruben A. Mesa, Rami S. Komrokji, Steffen Koschmieder, +10 more
8citations -
Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
Marc Steffen Raab, Niels Weinhold, Klaus Martin Kortüm, Jan Krönke, Lilli Podola, Uta Bertsch, +23 more
47citations -
Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis2023 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Naveen Pemmaraju, Adam J. Mead, Tim C. P. Somervaille, James K. McCloskey, Francesca Palandri, Steffen Koschmieder, +18 more
42citations -
POS0788 BIMEKIZUMAB DEMONSTRATED SUSTAINED EFFICACY AND SAFETY ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 3-YEAR RESULTS FROM TWO PHASE 3 STUDIES AND THEIR OPEN-LABEL EXTENSION2025 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access
X. Baraliakos, A. Deodhar, Désirée M F M van der Heijde, Filip E Van den Bosch, M. Magrey, Walter P. Maksymowych, +6 more
1citations -
MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly2020 Journal of the Endocrine Society article Medicine Pituitary Gland Disorders and Treatments Open access
Susan Leanne Samson, Lisa B. Nachtigall, Maria Fleseriu, Murray B. Gordon, Mojca Jensterle, Atanaska P. Elenkova, +8 more
0citations -
Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
Andreas Burchert, Susanne Saußele, Stephan Metzelder, Andreas Hochhaus, Norbert Gattermann, Martina Margrit Crysandt, +27 more
13citations -
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Hartmut Goldschmidt, Eva Nievergall, Roland R. Fenk, Uta Bertsch, Diana Tichy, Britta Besemer, +25 more
33citations -
Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial
Antonio Maria Risitano, Austin Gladston Kulasekararaj, Alexander Roeth, Phillip Scheinberg, Yutaka Ueda, Eros Di Bona, +29 more
14citations -
MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
2citations -
P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +11 more
1citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
1citations -
POS0773 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS OR PSORIATIC ARTHRITIS TREATED WITH BIMEKIZUMAB: LONG-TERM RESULTS FROM PHASE 2B/3 TRIALS2025 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access
Irene E. van der Horst-Bruinsma, Matthew Brown, Floris A van Gaalen, Nigil Haroon, L. S. Gensler, Alexander Marten, +5 more
2citations -
Adverse events and their management in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, after longer-term follow-up from the global phase 3 MANEUVER trial.2026 Journal of Clinical Oncology conference-abstract Medicine Musculoskeletal synovial abnormalities and treatments Open access
Vinod Ravi, Vishal Ghori, Aimar Zhang, Niki Karachaliou, Hans A. J. Gelderblom, Qingping Zou, +2 more
0citations